03 nov: Nye Endelige Vilkår til Nykredit Realkredit A/S' Basisprospekt af..
03 nov: Aktietilbagekøb
03-11-2017 09:26:27

ALK appoints Søren Jelert as new Chief Financial Officer

Relateret indhold
14 sep - 
ALK-Abelló/Kempen: Reducerer til "sælg" og fastholder k..
14 sep - 
ALK-Abelló: Amerikanere reducerer sats på kursfald
13 sep - 
Torsdagens aktier: Japansk udfald mod Ambu trak aktien ..
Relateret debat
22 aug - 
Der hvor jeg tror man undervurderer potentialet er hast..
22 aug - 
Den har ihvertfald lavet et GC d. 08.06.2018, og både k..
22 aug - 
Alk brager nu igennem 1200. Men hvor langt skal den op ..

 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Søren Jelert as its new Chief Financial Officer (CFO) and Executive Vice President.

 

From 2008 until 2016, Søren Jelert, who is 45, was CFO at NNE, an engineering company that specialises in supporting pharmaceutical company engineering projects. Since 2016, he has been General Manager of NNE's US organisation. His career has also included various finance roles at Novo Nordisk and Maersk. 

 

Carsten Hellmann, ALK’s President and CEO, said: “Søren Jelert brings a wealth of experience to ALK, in particular, from his previous pharmaceutical industry-focused roles at NNE and Novo Nordisk. He has a proven track record of financial leadership and he has also played a pivotal role in transformation processes that are comparable to the one we are embarking upon at ALK.”

 

Søren will be based at ALK’s headquarters in Hørsholm, Denmark and will report directly to Carsten Hellmann. He is expected to take up his new role by 2 January 2018.

 

Søren commented: "This new role offers me the opportunity to use my knowledge and experience to support and further develop ALK as it works to build a new growth platform and to become a truly global allergy company."

 

Søren Jelert succeeds Flemming Pedersen, whose decision to leave ALK was announced in July 2017.  

 

ALK-Abelló A/S

 

For further information please contact:

Carsten Hellmann, President & CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachments:

https://www.globenewswire.com/NewsRoom/AttachmentNg/67095a20-1bd8-4156-9150-23d9b618a49d

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Alm. Brand og Topdanmark hæves til "køb" af Danske Markets - NY

24-09-2018 10:03:34
Danske Markets hæver anbefalingen af aktierne i de to forsikringsselskaber Alm. Brand og Topdanmark.I begge tilfælde er anbefalingen hævet til "køb" fra tidligere "hold", fremgår det af Bloomberg News. Kursmålet for Topdanmark-aktien er justeret op til 320 kr. fra før 300 kr., mens 12-måneders kursmålet for Alm. Brands aktie er fastholdt på 64 kr. Danske Markets gentager i øvrigt en købsanbefaling..

Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt

24-09-2018 08:26:39
Coloplast og Mærsk kan komme i rampelyset mandag morgen, hvor de fortsatte handelsstridigheder mellem USA og Kina også vil være et af dagens store samtaleemner efter nye tariffer og en kinesisk afvisning af at deltage i nye handelsforhandlinger.Det tyder også på, at de danske eliteaktier skal en tur ned mandag morgen, hvor markedet igen er præget af den seneste udvikling i handelsstriden mellem US..

Danske: Moody's ser risiko for sænkning af kreditvurderingen - NY

21-09-2018 15:14:23
Moody's Investors Service er gået i gang med at kigge kreditvurderingen af Danske Bank efter i sømmene og forudser, at der er risiko for en nedjustering. Det oplyser ratinginstituttet fredag, hvor udsigten for Danske Banks kreditvurdering er sænket til "negativ" fra "stabil".Ændringen kommer, efter at banken har offentliggjort rapporten om hvidvask i sin estiske filial tidligere på ugen, skriver M..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank-investorer sætter aktien på vippen - citat
2
ECB/Nordea: Markedet gearer op til et høgeagtigt skift
3
Danske Bank er millimeter fra at udpege ny topchef - citat
4
Aktier/tendens: Mærsk og Coloplast i fokus midt i handelskonflikt
5
Aktier/middag: Ambu og Danske ryger til bunds i nervøst aktiemarked

Relaterede aktiekurser

ALK-Abelló B A/S 1.102,00 -2,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. september 2018 05:02:27
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB3 - 2018-09-25 05:02:27 - 2018-09-25 05:02:27 - 1 - Website: OKAY